Close Menu

NEW YORK ─ Sunnyvale, California-based Cepheid on Tuesday announced it has obtained CE-IVD marking for its Xpert Xpress SARS-CoV-2/Flu/RSV rapid molecular diagnostic test to detect from a single patient sample the viruses that cause COVID-19, Flu A, Flu B, and RSV infections.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Italy has held talks with vaccine developers to manufacture mRNA-based SARS-CoV-2 vaccines, according to the Financial Times.

The Associated Press reports US officials are removing restrictions on fetal tissue research that were added during the Trump Administration.

The Biden Administration is investing $1.7 billion to detect and monitor SARS-CoV-2 variants.

In PLOS this week: genome instability in Aicardi-Goutières Syndrome, introduction of SARS-CoV-2 to the Colombian Amazon, and more.